Photocure ASA announced the presentation of clinical data from the Veterans Affairs (VA) BRAVO study at the ASCO Genitourinary Cancers Symposium (ASCO GU) which was held February 16-18, 2023 in San Francisco, USA. The clinical data demonstrated a significant decrease in the risk of recurrence & longer time to recurrence following Blue Light cystoscopy (BLC®) with Cysview® compared to White Light cystoscopy (WLC) alone. The study was conducted with support from Photocure and aims to describe bladder cancer outcomes and the impact of blue light cystoscopy (BLC®) with Cysview® among non-muscle invasive bladder cancer (NMIBC) patients in an equal access setting, i.e., the United States Veterans Affairs Healthcare System (VA).

Patients diagnosed with NMIBC within the VA who received BLC were assessed to determine overall recurrence rates as well as the association between race and recurrence, progression, and overall survival outcomes. A total of 378 patients were included in the analysis, of which 43 (11%) were African American and 300 (79%) were Caucasian. The results showed that the median time to first recurrence following BLC vs.

WLC was significantly longer overall (40 vs. 26 months, p<0.001) and across all time points, respectively, in the cohort. A significant decrease in risk of recurrence following BLC utilization compared to WLC alone was also determined (HR, 0.70, p=0.005).

With regard to race stratification, the analysis showed no significant difference between African American and Caucasian patients for recurrence, progression and overall survival.